ametumumab + anti-PD-1 monoclonal antibody + FOLFIRI

**ametumumab + anti-PD-1 monoclonal antibody + FOLFIRI** is a combination regimen comprising three distinct therapeutic entities for cancer treatment. - **Ametumumab** is a monoclonal antibody (most likely targeting a tumor-associated antigen, but specific mechanism and indications are not established in the provided sources). - **Anti-PD-1 monoclonal antibody** refers to immunotherapy agents that block the programmed death-1 (PD-1) receptor, thereby enhancing T-cell mediated immune responses against tumor cells. Examples include pembrolizumab and nivolumab, but the specific agent here is unspecified. - **FOLFIRI** is a standard intravenous chemotherapy regimen including folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. - **Leucovorin** enhances 5-FU activity by increasing its binding to thymidylate synthase. - **Fluorouracil (5-FU)** is an antimetabolite that disrupts DNA synthesis, causing cancer cell death[1][2][3]. - **Irinotecan** inhibits topoisomerase I, blocking DNA replication and leading to cell death[1][2][3]. - **The mechanism of combined therapy:** The regimen is designed to exert cytotoxic effects (FOLFIRI) and modulate immune checkpoints (anti-PD-1), potentially increasing the immune system’s ability to recognize and destroy cancer cells, ideally improving efficacy compared to chemotherapy or immunotherapy alone. This approach is most relevant for advanced/metastatic colorectal cancer and other solid tumors treatable by these classes.